Donafenib Tosylate

甲苯磺酸多纳非尼

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameDonafenib Tosylate
Drug Alias NameDonafenib多纳非尼DonafeibDonafenib tosilate泽普生 +[9] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs
Mechanisms of ActionReceptor protein-tyrosine kinase inhibitorsRAF serine/threonine protein kinase inhibitorsVascular endothelial growth factor receptor inhibitors +[4] 
TargetsVascular endothelial growth factor receptorPlatelet-derived growth factor receptorReceptor protein-tyrosine kinase +[4] 
Therapy Area/IndicationsSolid tumoursThyroid NeoplasmsStomach Neoplasms +[10] 
Global Approved IndicationsCarcinoma, Hepatocellular
Approved Indications in ChinaCarcinoma, Hepatocellular
Original Approved Country/TerritoryMainland China
Original Approved Date2021/06/08
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSuzhou Zelgen Biosciences Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Zelgen Biopharmaceuticals Co LtdChina National Medicines Corporation Ltd
Inactive CompaniesFudan UniversityZhejiang University
Active IndicationsSolid tumoursThyroid NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsStomach NeoplasmsColorectal NeoplasmsEsophageal Neoplasms +[7] 

Other Information

ATC CodeL01X
Related LinksWikipediaDrugBank